Nurix Therapeutics, Inc. NRIX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s investment proceeds?
- Nurix Therapeutics, Inc. (NRIX) reported investment proceeds of $133.15M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Nurix Therapeutics, Inc.'s investment proceeds decreased by 4.3% year-over-year, from $139.2M to $133.15M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s investment proceeds has grown at a 26.8% compound annual growth rate (CAGR), from $238.91M to $617.54M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.